43.98
-0.31 (-0.70%)
| Previous Close | 44.29 |
| Open | 43.98 |
| Volume | 1,539,558 |
| Avg. Volume (3M) | 914,496 |
| Market Cap | 3,353,368,832 |
| Price / Sales | 5.22 |
| Price / Book | 4.53 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Operating Margin (TTM) | -81,161.54% |
| Diluted EPS (TTM) | -1.50 |
| Quarterly Revenue Growth (YOY) | -90.20% |
| Total Debt/Equity (MRQ) | 0.15% |
| Current Ratio (MRQ) | 30.97 |
| Operating Cash Flow (TTM) | -81.98 M |
| Levered Free Cash Flow (TTM) | -57.18 M |
| Return on Assets (TTM) | -12.85% |
| Return on Equity (TTM) | -16.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | CG Oncology, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -4.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 4.0 |
| Average | 2.00 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.17% |
| % Held by Institutions | 105.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Decheng Capital Llc | 30 Jun 2025 | 6,371,669 |
| Foresite Capital Management Vi Llc | 30 Jun 2025 | 2,221,474 |
| Orbimed Advisors Llc | 30 Jun 2025 | 1,877,850 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (Guggenheim, 104.64%) | Buy |
| Median | 75.00 (70.53%) | |
| Low | 47.00 (JP Morgan, 6.87%) | Buy |
| Average | 67.29 (53.00%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 34.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 08 Oct 2025 | 90.00 (104.64%) | Buy | 40.71 |
| JP Morgan | 26 Sep 2025 | 47.00 (6.87%) | Buy | 37.54 |
| Morgan Stanley | 17 Sep 2025 | 79.00 (79.63%) | Buy | 37.72 |
| HC Wainwright & Co. | 15 Sep 2025 | 75.00 (70.53%) | Buy | 34.60 |
| 08 Sep 2025 | 75.00 (70.53%) | Buy | 33.69 | |
| Cantor Fitzgerald | 08 Sep 2025 | 75.00 (70.53%) | Buy | 33.69 |
| Jones Trading | 08 Sep 2025 | 50.00 (13.69%) | Buy | 33.69 |
| Piper Sandler | 19 Aug 2025 | 55.00 (25.06%) | Buy | 25.56 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Sep 2025 | Announcement | CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months |
| 03 Sep 2025 | Announcement | CG Oncology Completes Enrollment in PIVOT-006 |
| 29 Aug 2025 | Announcement | CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences |
| 08 Aug 2025 | Announcement | CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates |
| 29 Jul 2025 | Announcement | Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |